| Biomarker ID | 1955 |
| PMID | 22589488 |
| Year | 2012 |
| Biomarker | Methylation status of HIF3A |
| Biomarker Basis | Methylation Based |
| Biomolecule | Methylation |
| Source | Tissue |
| Subjects | Humans |
| Regulation | Differentially Methylated between PCa and Normal |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | NA |
| Experiment | Tumor Vs Normal Tissues |
| Type of Biomarker | Diagnostic |
| Cohort | 198 Prostate Cancer and 40 matched normal tissues; Validation: 20 cancer and 20 Normal |
| Senstivity | Training: 95.6 (91.1–98.2) ; Validation 90.0 (68.3-98.77) |
| Specificity | Training:100 (89.7–100); validation: 100 (83.1–100) |
| AUC | Training: 0.989; Validation: 0.932 |
| Accuracy | NA |
| Level Of Significance | <0.0001 |
| Method Used | Pyrosequencing |
| Clinical | No |
| Remarks | NA |
| Clinical Trial Number | NA |
| Degree Of Validity | Validated on independent patient dataset |
| Technical Name | HIF3A |